Ticker > Company >

Neuland Laboratories share price

Neuland Laboratories Ltd.

NSE: NEULANDLAB BSE: 524558 SECTOR: Pharmaceuticals & Drugs  1.57 L   318   34

13824.00
+87.35 (0.64%)
BSE: 28 Jul 04:01 PM

Price Summary

Today's High

₹ 14089.3

Today's Low

₹ 13725.95

52 Week High

₹ 18089.55

52 Week Low

₹ 8283

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

17736.04 Cr.

Enterprise Value

17614.78 Cr.

No. of Shares

1.28 Cr.

P/E

68.37

P/B

11.69

Face Value

₹ 10

Div. Yield

0.09 %

Book Value (TTM)

₹  1182.3

CASH

257.27 Cr.

DEBT

136.01 Cr.

Promoter Holding

32.68 %

EPS (TTM)

₹  202.2

Sales Growth

-5.24%

ROE

18.58 %

ROCE

23.49%

Profit Growth

-13.41 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-5.24%
3 Year15.8%
5 Year14.13%

Profit Growth

1 Year-13.41%
3 Year59.83%
5 Year74.84%

ROE%

1 Year18.58%
3 Year20.99%
5 Year16.33%

ROCE %

1 Year23.49%
3 Year26.04%
5 Year20.08%

Debt/Equity

0.0897

Price to Cash Flow

55.86

Interest Cover Ratio

42.6318

CFO/PAT (5 Yr. Avg.)

1.23071885590375

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 32.68 0.00
Mar 2025 32.68 0.00
Dec 2024 32.68 0.00
Sep 2024 32.64 0.00
Jun 2024 32.72 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 59.8343549108334% for the Past 3 years.
  • The company has shown a good revenue growth of 15.7990726989542% for the Past 3 years.
  • Company has been maintaining healthy ROE of 20.9870666666667% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.0354666666667% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 42.6318.
  • The Company has been maintaining an effective average operating margins of 20.9636164739014% in the last 5 years.
  • The company has an efficient Cash Conversion Cycle of 33.4604 days.
  • Company has a healthy liquidity position with current ratio of 2.4064.
  • The company has a good cash flow management; CFO/PAT stands at 1.23071885590375.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.66361051627282.

 Limitations

  • The company is trading at a high PE of 68.37.
  • The company is trading at a high EV/EBITDA of 51.3839.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 385.01 439.6 310.84 398.03 328.36
Total Expenditure 278.22 315.78 249.5 311.66 277.61
Operating Profit 106.79 123.83 61.34 86.38 50.75
Other Income 5.36 4.81 4.33 3.91 7.46
Interest 3.61 2.67 1.06 2.22 2.35
Depreciation 16.46 16.28 16.07 16.3 16.89
Exceptional Items 0 20.63 0 55.78 0
Profit Before Tax 92.08 130.31 48.54 127.55 38.98
Tax 24.47 31.97 16.58 26.15 11.25
Profit After Tax 67.61 98.34 31.96 101.39 27.73
Adjusted EPS (Rs) 52.4 76.23 24.77 78.59 21.5

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 936.91 951.08 1191.2 1558.58 1476.84
Total Expenditure 790.47 808.88 919.89 1096.66 1154.54
Operating Profit 146.44 142.19 271.31 461.92 322.3
Other Income 16.09 2.08 9.75 12.54 20.51
Interest 17.9 13.49 13.07 14 8.3
Depreciation 39.68 49.04 52.78 59.7 65.54
Exceptional Items 0 0 0 0 76.4
Profit Before Tax 104.96 81.74 215.21 400.77 345.37
Tax 24.67 18.21 52.09 101.17 85.95
Net Profit 80.29 63.53 163.12 299.6 259.43
Adjusted EPS (Rs.) 62.58 49.52 127.14 233.51 202.2

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 12.9 12.9 12.9 12.9 12.9
Total Reserves 768.98 822.67 975.46 1263.64 1504.89
Borrowings 88.13 104.25 74.25 44.92 90.73
Other N/C liabilities 80.54 74.17 70.98 75.67 96.82
Current liabilities 372.96 368.13 445.75 433.8 472.84
Total Liabilities 1323.52 1382.12 1579.34 1830.93 2178.17
Assets
Net Block 696.92 747.7 738.19 804.63 954.89
Capital WIP 17.25 20.46 40.57 45.89 44.55
Intangible WIP 0 0 0 0 3.11
Investments 0.6 0.66 0.68 1.44 1.69
Loans & Advances 41.66 14.4 20.21 40.31 35.88
Other N/C Assets 18.91 19.66 19.34 19.19 0.23
Current Assets 548.18 579.25 760.34 919.47 1137.82
Total Assets 1323.52 1382.12 1579.34 1830.93 2178.17
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 104.96 81.74 215.21 400.77 345.37
Adjustment 40.17 66.18 77.93 62.07 -12.01
Changes in Assets & Liabilities 49.34 -66.99 -11.04 -91.22 58.75
Tax Paid -5.19 -20.53 -43.57 -111.57 -74.62
Operating Cash Flow 189.28 60.41 238.53 260.06 317.49
Investing Cash Flow -84.42 -95.53 -61.5 -149.67 -298.14
Financing Cash Flow -113.66 37.72 -135.8 -69.28 24.96
Net Cash Flow -8.8 2.6 41.24 41.11 44.31

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 32.72 32.64 32.68 32.68 32.68
davuluri ownership trust ... - - - - 25.98
davuluri rohini niveditha... 0.67 0.67 0.67 0.67 0.67
davuluri saharsh rao 2.24 2.24 2.24 1.62 1.62
davuluri sucheth rao 2.63 2.63 2.63 2.01 2.01
davuluri vijaya rao 4.78 4.78 4.78 0.04 0.04
gannabathula uma bala 0.05 0.05 0.05 0.05 0.05
gannabathula veeravenkata... 0.17 0.17 0.17 0.17 0.17
gannabathula venkata kris... 0.27 0.25 0.25 0.25 0.25
ramamohan rao davuluri 21.59 21.59 21.63 1.63 1.63
usha rani reddy chevalla 0.32 0.27 0.27 0.26 0.26
davuluri ownership trust - - - 25.98 -
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 67.28 67.36 67.32 67.32 67.32
hsbc balanced advantage f... - - 3.06 - 2.39
icici prudential s&p bse ... - - - - 1.78
investor education and pr... - - - 0.35 0.35
jupiter india fund 1.12 1.12 1.33 1.29 1.29
kedia securities private ... 1.09 1.01 1.01 1.01 1.01
malabar india fund limite... 8.86 6.08 5.76 5.76 5.76
matthews india fund 1.68 1.76 1.76 1.31 1.04
mukul mahavir agrawal 3.12 3.12 3.12 3.12 3.12
siddharth iyer 1.49 1.69 1.73 1.62 1.62
hsbc focused fund - - - 2.92 -
icici prudential flexicap... - - - 1.33 -
investor education and pr... 0.37 0.24 0.36 - -
hsbc small cap fund - 2.56 - - -
smallcap world fund, inc 1.08 3.77 - - -
hsbc multi cap fund 2.71 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit FITCH
Credit FITCH
Credit CRISIL
Credit FITCH
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BP Wealth

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY22
Concall Q3FY24
Concall Q3FY23
Concall Q2FY23
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q3FY24
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY21
Presentation Q1FY22
Presentation Q1FY21

Company News

Neuland Laboratories Stock Price Analysis and Quick Research Report. Is Neuland Laboratories an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Neuland Laboratories and its performance over the period of time. Neuland Laboratories stock price today is Rs 13875.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Neuland Laboratories cash from the operating activity was Rs 317.4895 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Neuland Laboratories has a Debt to Equity ratio of 0.0897 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Neuland Laboratories , the EPS growth was -13.4083 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Neuland Laboratories has OPM of 21.8235888272865 % which is a good sign for profitability.
     
  • ROE: Neuland Laboratories have a average ROE of 18.5801 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Neuland Laboratories is Rs 13875. One can use valuation calculators of ticker to know if Neuland Laboratories share price is undervalued or overvalued.
Last Updated on:
Brief about Neuland Laboratories
X